论文部分内容阅读
1984年,Burke等人就报告,钙通道阻滞剂(CCB)可以保护组织免受缺血性损害。1987年,Wagner等人经实验研究和临床试验证明硫氮酮可预防尸体移植肾的缺血性损害和减少移植肾功能延迟的发病率,并提出硫氮酮治疗可减少环孢素A的用量及其肾毒性。Renton认为,环孢素A和CCB都由同一种肝脏同功酶P-450PCNI代谢,因而硫氮酮可使环孢素A血浓度升高。Neumayer,Davidson等人(1989)经短期和长期的前瞻性研究证实,使用CCB同时减少环孢素A剂量仍然可保持环孢素A的血浓度在治疗范围。南斯拉夫贝尔格莱德大学医疗中心进行一组前瞻性研究,将25例活体亲属肾移植患者随机分成两
In 1984, Burke et al. Reported that calcium channel blockers (CCBs) protect tissues from ischemic damage. In 1987, Wagner et al., Through experimental studies and clinical trials, proved that diazinon could prevent the ischemic injury of cadaveric renal graft and reduce the incidence of delayed renal graft function. It was also suggested that treatment with azathione could reduce cyclosporine A The amount and its nephrotoxicity. According to Renton, both cyclosporin A and CCB are metabolized by the same hepatic isozyme P-450PCNI, and thus thiazide increases cyclosporin A blood levels. Neumayer, Davidson et al. (1989) confirmed short-term and long-term prospective studies that using CCB while reducing cyclosporine A dose still maintained the blood concentration of cyclosporin A within the therapeutic range. A prospective study conducted by the Medical Center at Belgrade University in Yugoslavia divided 25 living-related kidney transplant patients into two